Among the first three predicted TFs that may bind and affect the transcription of CTNNA2, Foxo3 was reported to be neuroprotective [27] in neurodegenerative diseases like Parkinson's [28] and Huntington's disease [29]. This evidence concerns the gene FOXO3 and juvenile Huntington disease.